Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA9 | Q16790 | 13/20 | 0.59 |
| ▸ | CA1 | P00915 | 12/20 | 0.54 |
| ▸ | CA2 | P00918 | 12/20 | 0.54 |
| ▸ | CA12 | O43570 | 7/20 | 0.54 |
| ▸ | HTR3A | P46098 | 2/20 | 0.52 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.51 |
| ▸ | CA7 | P43166 | 1/20 | 0.51 |
| ▸ | USP2 | O75604 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.49 |
| ▸ | PTGER3 | P43115 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 2/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18163373 | 0.87 | CA9 (0.68) | CA9CA1CA2CA12HTR3A | |
| SCHEMBL15502951 | 0.85 | CA1 (0.63) | CA9CA1CA2CA12HTR3A | |
| SCHEMBL18163355 | 0.82 | CA9 (0.55) | CA9CA1CA2CA12HTR3A | |
| SCHEMBL17522975 | 0.82 | CA9 (0.73) | CA9CA1CA2CA12CA14 | |
| SCHEMBL18624613 | 0.80 | CA1 (0.64) | CA9CA1CA2CA12HTR3A | |
| SCHEMBL21728989 | 0.80 | CA9 (0.73) | CA9CA1CA2CA12HTR3A | |
| SCHEMBL21151146 | 0.80 | CA9 (0.73) | CA9CA1CA2CA12HTR3A | |
| SCHEMBL21282083 | 0.80 | CA1 (0.70) | CA9CA1CA2CA12HTR3A | |
| SCHEMBL22855043 | 0.80 | CA1 (0.70) | CA9CA1CA2CA12HTR3A | |
| SCHEMBL17245251 | 0.80 | CA1 (0.70) | CA9CA1CA2CA12HTR3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210221880-A1 | CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF | GUANGZHOU LAMGENE BIOMEDICAL TECHNOLOGY CO., LTD. (CN) | 2021-07-22 | — | — | US | disclosed |
| US-20180100026-A1 | OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2018-04-12 | — | — | US | disclosed |
| US-20180100026-A1 | OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH | 2018-04-12 | — | — | US | disclosed |
| WO-2016168769-A1 | CHIMERIC RECEPTOR T CELL SWITCHES FOR HER2 | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-10-20 | — | — | WO | disclosed |
| WO-2016168766-A1 | OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF | THE CALIFORNIA INSTITUTE FOR BIOMEDICAL RESEARCH (US) | 2016-10-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180100026-A1 | OPTIMIZED CHIMERIC RECEPTOR T CELL SWITCHES AND USES THEREOF | ICOS, HAVCR2, TNFRSF9 | CA9 1308/4885CA1 3135/4885CA2 4003/4885 |
| US-20210221880-A1 | CHIMERIC ANTIGEN RECEPTOR AND APPLICATION THEREOF | HAVCR2, TAP2, CD47 | CA9 3118/4885CA1 1692/4885CA2 1219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.